TLDR Citrea launched its mainnet to enable lending trading and USD settlement directly on the Bitcoin network. The platform introduced ctUSD a U.S. dollar stablecoinTLDR Citrea launched its mainnet to enable lending trading and USD settlement directly on the Bitcoin network. The platform introduced ctUSD a U.S. dollar stablecoin

Citrea Debuts Mainnet and ctUSD Stablecoin to Power Bitcoin Finance

2026/01/28 00:25
3 min read

TLDR

  • Citrea launched its mainnet to enable lending trading and USD settlement directly on the Bitcoin network.
  • The platform introduced ctUSD a U.S. dollar stablecoin issued by MoonPay and powered by M0.
  • ctUSD is fully backed by short-term U.S. Treasury bills and cash held in reserve.
  • Citrea designed ctUSD to align with the upcoming GENIUS Act compliance framework.
  • The mainnet supports BTC-backed lending and BTC-denominated structured financial products.

Citrea has launched its mainnet to bring lending, trading, and USD-denominated settlement to the Bitcoin network, aiming to unlock dormant capital and expand on-chain financial activity directly on Bitcoin through native applications and services.

ctUSD Stablecoin Launches to Power Bitcoin-based Settlement

Citrea introduced ctUSD, a new U.S. dollar–denominated stablecoin, alongside the mainnet. MoonPay issues the token, and M0 powers its infrastructure.

The stablecoin is fully backed by short-term U.S. Treasury bills and cash, providing transparency and liquidity for users across the platform. Citrea confirmed ctUSD aligns with the upcoming GENIUS Act to help ensure future compliance.

MoonPay and M0 collaborated to ensure the stablecoin maintains full reserves while integrating seamlessly with Bitcoin-native applications. This enables users to engage in financial operations using dollar-denominated assets.

Citrea positioned ctUSD as a compliant and efficient layer for settlement on the Bitcoin network. The goal is to support a wide range of financial tools.

MoonPay’s involvement aims to bridge fiat and crypto more efficiently. The stablecoin is already live and available for use on Citrea’s platform.

Citrea Mainnet Launch Targets Bitcoin Lending and Trading

The new mainnet supports two primary products: BTC-backed lending and BTC-denominated structured products. These services offer new options for capital deployment.

Citrea built its lending infrastructure in collaboration with Morpho and UltraYield by Edge Capital. These partners helped create mechanisms that offer lending directly backed by Bitcoin.

Keyrock, a digital asset market maker, is working with Citrea to design BTC-denominated structured yield strategies. These products combine off-chain components with on-chain execution.

He emphasized Citrea enables Bitcoin-native capital management.

The mainnet enables users to engage in structured finance without relying on external chains. All settlement and collateralization happen directly on Bitcoin.

Citrea confirmed over 30 Bitcoin-native applications are ready to launch. These span institutional and retail finance, covering lending, trading, and settlement functions.

Bitcoin Network Sees Expanded Utility Through Citrea Integration

Citrea seeks to address the lack of native financial infrastructure on Bitcoin. Over 61% of BTC has not moved in more than a year.

This represents over $1.2 trillion in idle capital, according to on-chain data. Citrea aims to mobilize that capital through programmable finance.

She added the platform leverages Bitcoin’s security.

Galaxy Ventures partner Will Nuelle supported the project’s potential to draw institutional users. He noted that on-chain capital markets and stablecoin access may deepen network engagement.

The post Citrea Debuts Mainnet and ctUSD Stablecoin to Power Bitcoin Finance appeared first on CoinCentral.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26